ライフサイエンスコーパス: rifampin

1 d maybe also a potential benefit from adding rifampin.

2 und 26 is also shown to work in synergy with rifampin.

3 ine than in subjects receiving standard-dose rifampin.

4 gher rates of hepatotoxicity than placebo or rifampin.

5 s of S. aureus in infected mice treated with rifampin.

6 sistance of a poxvirus to the antiviral drug rifampin.

7 sis resistant to at least both isoniazid and rifampin.

8 nt in the presence of the assembly inhibitor rifampin.

9 e negative pharmacokinetic interactions with rifampin.

10 tween PDE-Is (cilostazol and sildenafil) and rifampin.

11 , or kanamycin, in addition to isoniazid and rifampin.

12 Nine patients were treated with TMP-SMX and rifampin.

13 esistant mutants were not cross-resistant to rifampin.

14 and absence of the RNA polymerase inhibitor rifampin.

15 One patient was taking only rifampin.

16 ch, media, RBT was 200-fold more potent than rifampin.

17 o anti-tuberculosis (TB) drugs isoniazid and rifampin.

18 s tolerance to the transcriptional inhibitor rifampin.

19 is simultaneously resistant to isoniazid and rifampin.

20 e months of isoniazid and 43% four months of rifampin.

21 l-antimicrobial therapy with a macrolide and rifampin.

22 g beta-lactams, and 37% of patients received rifampin.

23 starved cells but killed those generated by rifampin.

24 r 11 drugs: isoniazid (0.03 to 0.12 mug/ml), rifampin (0.03 to 0.25 mug/ml), ethambutol (0.25 to 2 mu

25 as monotherapy (0.48) or in combination with rifampin (0.34).

26 of removable components (0.60), early use of rifampin (0.98 per day of treatment within the first 30

27 09 if initially susceptible to isoniazid and rifampin, 1 in 113 if initially isoniazid resistant, and

28 assigned rifapentine 10, 15, or 20 mg/kg or rifampin 10 mg/kg daily for 8 weeks (intensive phase), w

29 ing the MDR-TB assay were 100% and 92.3% for rifampin, 100% and 93.8% for isoniazid, 91.6% and 94.4%

30 ) were initially prescribed isoniazid (73%), rifampin (12.7%), or another regimen (14.3%).

31 ntensified regimen that included higher-dose rifampin (15 mg per kilogram per day) and levofloxacin (

32 ental groups with 15 patients each receiving rifampin 20, 25, 30, and 35 mg/kg, respectively, for 14

33 sing IS-enabled combination isoniazid 150 mg/rifampin 300 mg (IS-Rifamate).

34 oniazid (6H), three months of isoniazid plus rifampin (3RH) and three months of isoniazid plus rifape

35 ever been compared with four months of daily rifampin (4R).

36 tment, prescribed daily isoniazid 300 mg and rifampin 600 mg, used IS-Rifamate.

37 Further, we show that rifampin (75 or 100 mg/kg b.i.d. for 3 d, intraperitonea

38 ic ineligibility were similar across groups (rifampin, 8.2%; rifapentine 10, 15, or 20 mg/kg, 3.4, 2.

39 results were 94.3% for isoniazid, 98.7% for rifampin, 97.6% for quinolones (ofloxacin, levofloxacin,

40 0)Z and HR(160)Z therapy regimens showed for rifampin a C(max) of 16.2 and 157.3 mg/L, an AUC(0-24h)

41 Rifampin, a semisynthetic rifamycin, is the cornerstone

42 moxifloxacin improved at higher pH, whereas rifampin activity was pH independent.

43 resistant to rifampin, and harbored arr-3, a rifampin adenosine diphosphate-ribosyl transferase.

44 first-in-human study(4) using dynamic [(11)C]rifampin (administered as a microdose) positron emission

45 resistant to rifampin and harbored arr-3, a rifampin ADP-ribosyl transferase.

46 ear dose-effect correlation was observed for rifampin after 3-week single-drug treatment.

47 azole (TMP-SMX) and rifampin, TMP-SMX alone, rifampin alone, or tetracycline alone.

48 Data on the safety and efficacy of rifampin among people living with HIV or other health co

49 ect testing of MTBDRplus on sputa was 4% for rifampin and 2% for isoniazid.

50 Serogroup and MIC to penicillin, rifampin and chloramphenicol were determined.

51 y contributed to the detection of phenotypic rifampin and fluoroquinolone resistance with negligible

52 cally identical, phenotypically resistant to rifampin and harbored arr-3, a rifampin ADP-ribosyl tran

53 pyrazinamide daily for 2 months, followed by rifampin and isoniazid daily for 4 months.

54 Low rifampin and isoniazid peak and AUC concentrations prece

55 y for Mycobacterium tuberculosis complex and rifampin and isoniazid resistance detection on clinical

56 ve genotypic susceptibility results for both rifampin and isoniazid were seen in 26% of MTBDRplus tes

57 ntensive phase and was continued, along with rifampin and isoniazid, during the continuation phase.

58 zinamide, and ethambutol followed by 4 mo of rifampin and isoniazid, with a 4-mo clofazimine-containi

59 treatments are anchored by two antibiotics, rifampin and isoniazid.

60 DST for rifampin and kanamycin from sputum samples yielded resul

61 ly bactericidal (isoniazid) and sterilizing (rifampin and pyrazinamide), and ethambutol to help preve

62 had concentration-dependent antagonism with rifampin and pyrazinamide, with an adjusted odds ratio f

63 tor of hPXR expression and the hPXR agonists rifampin and rilpivirine are chemical suppressors of miR

64 nt of hPXR target gene (CYP3A4) induction by rifampin and rilpivirine.

65 Three months of isoniazid plus rifampin and six-months of isoniazid are similarly cost-

66 increases the sensitivity of mycobacteria to rifampin and streptomycin.

67 icient to modulate L. plantarum tolerance to rifampin and the translational inhibitor erythromycin.

68 acts had isolates resistant to isoniazid and rifampin, and 41 (36.6%) contacts had isolates with resu

69 three-times-weekly therapy with a macrolide, rifampin, and ethambutol is a reasonable initial treatme

70 hat included clarithromycin or azithromycin, rifampin, and ethambutol.

71 Safety, pharmacokinetics of rifampin, and fall in bacterial load were assessed.

72 folP1, rpoB, and gyrA, targets for dapsone, rifampin, and fluoroquinolones, real-time PCR-HRM assays

73 cally identical, phenotypically resistant to rifampin, and harbored arr-3, a rifampin adenosine dipho

74 Use of vancomycin, penicillin, rifampin, and linezolid was associated with a higher haz

75 cin, trimethoprim, gentamicin, fusidic acid, rifampin, and mupirocin) performed by the routine clinic

76 , concurrent use of amiodarone, fluconazole, rifampin, and phenytoin compared with the use of NOACs a

77 Concurrent use of amiodarone, fluconazole, rifampin, and phenytoin with NOACs had a significant inc

78 high between-child variability of isoniazid, rifampin, and pyrazinamide concentrations: 110 (77%) com

79 activity of the first-line drugs isoniazid, rifampin, and pyrazinamide in THP-1 cells.

80 tal pharmacokinetic parameters of isoniazid, rifampin, and pyrazinamide were identified for each pati

81 gimens to the standard regimen of isoniazid, rifampin, and pyrazinamide, based on exponential decline

82 an the standard 3-drug regimen of isoniazid, rifampin, and pyrazinamide.

83 tomycin, linezolid, minocyline, tigecycline, rifampin, and trimethoprim/sulfamethoxazole.

84 Rifampin appears to be safe and as effective as isoniazi

85 .25, and 5.75 moxifloxacin, doxycycline, and rifampin are effective at preventing growth of C. burnet

86 or drug interactions, alternative agents to rifampin are needed for management of staphylococcal per

87 The dosage of 10 mg/kg/d rifampin, as currently used in the treatment of tubercul

88 Rifampin at a dose of 10 mg/kg was introduced in 1971 ba

89 ncentration-time curve (AUC) </= 363 mg.h/L, rifampin AUC </= 13 mg.h/L, and isoniazid AUC </= 52 mg.

90 Rifampin-based combinations exhibited an independent pro

91 for a median of 93 days, with similar use of rifampin-based combinations in MSSA- and MRSA-PJI.

92 region, an 81-base pair region encoding the rifampin binding site on the beta subunit of RNA polymer

93 Herein, we show that rifampin binds to myeloid differentiation protein 2 (MD-

94 Rifampin blocked TLR4 signaling induced by LPS, includin

95 en the virus was passaged in the presence of rifampin but was lost in the absence of the drug, sugges

96 sceptible to chloramphenicol, penicillin and rifampin, but almost 60% of isolates characterized in So

97 resistance to amoxicillin, tetracycline, and rifampin, but combinatorial analyses for rdxA gene trunc

98 levofloxacin, ethambutol, azithromycin, and rifampin (CLEAR) regimen or a comparative placebo regime

99 armacodynamic relationships of verapamil and rifampin coadministration in mice.

100 SA and MRSA prognoses, although the specific rifampin combinations may have had different efficacies.

101 weeks, followed by 18 weeks of isoniazid and rifampin (control group).

102 ange in antigen production when treated with rifampin, demonstrating drug susceptibility and resistan

103 Rifampin did not reduce the efavirenz Cmin.

104 97]); 65.66 for NOAC use alone vs 103.14 for rifampin (difference, 36.90 [99% CI, 1.59-72.22); and 56

105 Determination of optimal rifampin dosage in mice, resulting in maximum therapeuti

106 ur findings indicate that the currently used rifampin dosage in the therapy of TB is too low.

107 In our murine TB model a rifampin dosage of 80 mg/kg/d enabled a significant redu

108 ation might be achievable using an increased rifampin dose.

109 curve experiments provided estimates on the rifampin dosing required to achieve cure in 4 months.

110 required to compensate for concurrent use of rifampin during TB treatment.

111 robial activity and safety of rifapentine vs rifampin during the first 8 weeks of pulmonary tuberculo

112 monstrated independent temporal evolution of rifampin exposure trajectories in different lesions with

113 and demonstrated spatially compartmentalized rifampin exposures in pathologically distinct TB lesions

114 thin the same patients, with low cavity wall rifampin exposures.

115 rs should ideally evaluate for resistance to rifampin, fluoroquinolones, isoniazid, and pyrazinamide

116 ultured isolates phenotypically resistant to rifampin, fluoroquinolones, or aminoglycosides, but for

117 ents receiving the standard dose of 10 mg/kg rifampin, followed by consecutive experimental groups wi

118 ed risk differences (RD) from RCTs comparing rifampin for >/=9 months and 6 months.

119 tly with the increased use of macrolides and rifampin for chemoprophylaxis and the treatment of subcl

120 erythromycin, clarithromycin, azithromycin, rifampin, gentamicin, and doxycycline against 101 isolat

121 erapy, 40 of 254 participants (15.7%) in the rifampin group and 40 of 275 participants (14.5%) in the

122 ere negative in 81.3% of participants in the rifampin group versus 92.5% (P = 0.097), 89.4% (P = 0.29

123 Liquid cultures were negative in 56.3% (rifampin group) versus 74.6% (P = 0.042), 69.7% (P = 0.1

124 Compared with the rifampin group, the proportion negative at the end of in

125 omoter, and ahpC promoter (isoniazid), rpoB (rifampin), gyrA (fluoroquinolones), rrs and eis promoter

126 Clinically, rifampin has been found to possess immunomodulatory effe

127 Rifampin has been used for the treatment of bacterial in

128 cin and doxycycline being bacteriostatic and rifampin having bactericidal activity.

129 ed critical concentrations for isoniazid and rifampin in commercial broth-based systems.

130 indicate that MD-2 is a important target of rifampin in its inhibition of innate immune function and

131 We assessed dose-dependent activity of rifampin in single-drug treatment during 3 weeks.

132 in and/or rifapentine may be alternatives to rifampin in the clinical management of staphylococcal pe

133 Maximum tolerated dosage of rifampin in the murine TB was 160 mg/kg/d.

134 te mechanism for resistance of poxviruses to rifampin, indicates a direct relationship between A17 le

135 onsible for the immunosuppressive effects of rifampin is not known.

136 ciated with species typing and resistance to rifampin, isoniazid and fluoroquinolone antibiotics.

137 inamide, and clofazimine followed by 2 mo of rifampin, isoniazid, and clofazimine.

138 nes, which are responsible for resistance to rifampin, isoniazid, and fluoroquinolone, respectively.

139 receive systematic empirical treatment with rifampin, isoniazid, ethambutol, and pyrazinamide daily

140 ith resistance to four types of antibiotics (rifampin, isoniazid, fluoroquinolones, and aminoglycosid

141 lofazimine-containing regimen: 2 mo of daily rifampin, isoniazid, pyrazinamide, and clofazimine follo

142 egimen for TB treatment, i.e., 2 mo of daily rifampin, isoniazid, pyrazinamide, and ethambutol follow

143 codynamic (PK/PD) simulation model including rifampin, isoniazid, pyrazinamide, and ethambutol was de

144 Five genes-rpoB (rifampin), katG (isoniazid), pncA (pyrazinamide), gyrA (

145 Among participants receiving rifampin living with HIV, incidence was comparable to th

146 nistration of a macrolide antimicrobial with rifampin (MaR) to apparently healthy foals with pulmonar

147 The results also suggest that rifampin may be repositioned as an agent for the treatme

148 The use of rifampin may have contributed to homogenizing MSSA and M

149 , rpoB mutant progeny strains with confirmed rifampin monoresistance following antitubercular therapy

150 haracteristics and mortality associated with rifampin-monoresistant (RMR) TB in the United States.

151 drug resistance, underscoring the safety of rifampin monotherapy for latent tuberculosis.

152 tance was detected in a single animal in the rifampin monotherapy group.

153 ese isolates, with their known resistance to rifampin, NGS of pncA improved PZA resistance detection

154 (SNPs) that confer resistance to isoniazid, rifampin, ofloxacin, and moxifloxacin occur the most fre

155 rticipants were randomized 1:1 to 10 mg/kg/d rifampin or 5 mg/kg/d isoniazid.

156 incidence was similar among people receiving rifampin or isoniazid.

157 eeks and 12 months with either ciprofloxacin-rifampin or with doxycycline alone or doxycycline in com

158 r-positive specimens resistant to isoniazid, rifampin, or both according to the GenoType MTBDRplus as

159 i strains that were resistant to macrolides, rifampin, or both, resulting in impaired in vitro growth

160 erythromycin or clarithromycin; dronedarone; rifampin; or phenytoin.

161 tration-time curve <11.95 mg/L x hour and/or rifampin peak <3.10 mg/L were the best predictors of the

162 azinamide peak concentration <38.10 mg/L and rifampin peak concentration <3.01 mg/L.

163 uberculosis regimen (which included 10 mg of rifampin per kilogram of body weight per day) with an in

164 [(11)C]rifampin PET-CT was safe and demonstrated spatially comp

165 imulations have suggested that isoniazid and rifampin pharmacokinetic variability best explained poor

166 Rifapentine was more potent than rifampin prior to development of human-like pathology an

167 ulosis were treated with regimens containing rifampin, pyrazinamide, and ethambutol +/- a FQ for a me

168 One group of patients received isoniazid, rifampin, pyrazinamide, and ethambutol for 8 weeks, foll

169 and bactericidal effect rates for isoniazid, rifampin, pyrazinamide, and ethambutol were the same in

170 eceiving standard 4-drug therapy (isoniazid, rifampin, pyrazinamide, and ethambutol) in Brazil.

171 ons associated with resistance to isoniazid, rifampin, quinolones and injectable drugs in Mycobacteri

172 Therapeutic efficacy of a range of rifampin (R) dosages added to a regimen of isoniazid (H)

173 for MAC identification; 97.4% and 98.7% for rifampin(r) TB identification; 60.6% and 100% for isonia

174 ce for hepatoxicity comparing isoniazid with rifampin ranged from 3% to 7%, with a pooled RR of 3.29

175 ot significantly more active than a standard rifampin regimen, by the surrogate endpoint of culture s

176 This case report illustrates that rifampin represents an effective alternative to doxycycl

177 CI], 82.4% to 97.9%) sensitive for detecting rifampin resistance and 99.7% (95% CI, 98.3% to 99.9%) s

178 f M. tuberculosis The specific links between rifampin resistance and named lipid factors provide diag

179 ted for samples referred for confirmation of rifampin resistance detected by the Cepheid Xpert MTB/RI

180 Isoniazid resistance arose once and rifampin resistance emerged subsequently at least three

181 berculosis DNA and mutations associated with rifampin resistance in 5 of 7 participants with rifampin

182 tations offset fitness costs associated with rifampin resistance in LAM4/KZN.

183 The Xpert assay failed to detect rifampin resistance in vitro when <90% of the organisms

184 Here we describe a second pathway to rifampin resistance involving A17, a membrane protein th

185 d in both genetic backgrounds, we found that rifampin resistance mutations lead to altered concentrat

186 Most rifampin resistance occurs through the acquisition of mi

187 as to examine the effect of macrolide and/or rifampin resistance on intracellular replication of R. e

188 support CDC recommendations to confirm Xpert rifampin resistance results.

189 lecular beacon assay should greatly simplify rifampin resistance testing in clinical laboratories.

190 performance of the Xpert assay for detecting rifampin resistance using phenotypic drug sensitivity te

191 Specificity for rifampin resistance was 99.5% and NPV was 98.9%.

192 sensitivity of the Xpert assay for detecting rifampin resistance was assessed in vitro by testing cul

193 Rifampin resistance was detected by the Xpert assay in 5

194 Rifampin resistance was detected in a single animal in t

195 The sensitivity and specificity for rifampin resistance were 100% and 100%, respectively, an

196 this assay's sensitivity and specificity for rifampin resistance were 85.7% (95% CI, 57.2, 98.2) and

197 DR-Plus, the sensitivity and specificity for rifampin resistance were 91.7% and 96.6%, respectively,

198 All forms of rifampin resistance were positively associated with HIV

199 increased false-negative rate for detecting rifampin resistance with mixed MTBC infections.

200 ably suppressed the defects in OM integrity, rifampin resistance, survival in macrophages, and system

201 For both classifications of rifampin resistance, we calculated adjusted risk ratios

202 rrelation of fluoroquinolone resistance with rifampin resistance, with sensitivity analysis for other

203 MTB/RIF Ultra assay detects mutations in the rifampin resistance-determining region (RRDR) of the rpo

204 Previously identified mutations in the rpoB rifampin resistance-determining region (RRDR) were not p

205 the acquisition of missense mutations in the rifampin resistance-determining region, an 81-base pair

206 osis as well asrpoBmutations associated with rifampin resistance.

207 the wild-type virus was sufficient to confer rifampin resistance.

208 rrelation of fluoroquinolone resistance with rifampin resistance.

209 ified 222/225 rifampin-resistant isolates as rifampin resistant (sensitivity, 98.7%; 95% CI, 95.8 to

210 hen <90% of the organisms in the sample were rifampin resistant.

211 susceptibility testing and possible acquired rifampin-resistant (ARR) TB.

212 Consequently, we found that the frequency of rifampin-resistant (Rif(r)) mutants is dramatically incr

213 tiate between DNA sequences of wild-type and rifampin-resistant (Rif(r)) Mycobacterium tuberculosis (

214 The assay identified 222/225 rifampin-resistant isolates as rifampin resistant (sensi

215 In several rifampin-resistant isolates, Ion Torrent sequencing reve

216 vel mutations outside the RRDR were found in rifampin-resistant isolates.

217 rium leprae and 1 of these patients also had rifampin-resistant M. leprae.

218 unctive transferrin reduced the emergence of rifampin-resistant mutants of S. aureus in infected mice

219 mately 10,000 cell wall lipids in a panel of rifampin-resistant mutants within two genetically distin

220 Molecular surveillance of rifampin-resistant Mycobacterium tuberculosis can help t

221 ng a principal screening tool for diagnosing rifampin-resistant Mycobacterium tuberculosis complex (M

222 to their superior affinity for wild-type and rifampin-resistant Mycobacterium tuberculosis RNA polyme

223 increase in the incidence of macrolide- and rifampin-resistant R. equi isolates has been documented.

224 umbers over time and the dual macrolide- and rifampin-resistant strain exhibited decreased proliferat

225 to DD Mtb generation, an effect lacking in a rifampin-resistant strain with a mutation in rpoB, which

226 acteristic remodeling of cell wall lipids in rifampin-resistant strains of M. tuberculosis The specif

227 . equi isolate outcompeted the macrolide- or rifampin-resistant strains.

228 sal FQ-DST, or FQ-DST only for patients with rifampin-resistant TB ("targeted FQ-DST").

229 e of FQ-DST, or FQ-DST only in patients with rifampin-resistant TB ('targeted FQ-DST').

230 across 25 countries with confirmed pulmonary rifampin-resistant TB were used for this guideline.

231 This unique, rifampin-resistant transcriptional machinery is conserve

232 In persons with rifampin-resistant tuberculosis that was susceptible to

233 3 noninferiority trial in participants with rifampin-resistant tuberculosis that was susceptible to

234 Until now, all known rifampin-resistant vaccinia virus isolates have containe

235 After one round of selection, a rifampin-resistant virus that contained a genomic duplic

236 ampin resistance in 5 of 7 participants with rifampin-resistant, culture-positive tuberculosis.

237 sis (wild type) to those of their respective rifampin-resistant, rpoB mutant progeny strains with con

238 iepileptic drugs and the antimicrobial agent rifampin, resulting in drug-induced osteomalacia, which

239 henotypic DST (true resistance) was 100% for rifampin (RIF) (14/14), 90.0% for isoniazid (INH) (36/40

240 of a highly conserved regulatory motif, the rifampin (RIF) -associated element (RAE), which is found

241 n version 1 [V1]) for the rapid detection of rifampin (RIF) and isoniazid (INH) resistance.

242 MTB/RIF for detection of M. tuberculosis and rifampin (RIF) resistance in sputum.

243 culosis (MTB) and detect isoniazid (INH) and rifampin (RIF) resistance.

244 ulosis (MTB), and detect isoniazid (INH) and rifampin (RIF) resistance.

245 Rifampin (RIF) upregulates CYP 450 isoenzymes, potential

246 Streptomycin (STR), isoniazid (INH), rifampin (RIF), ethambutol (EMB) (collectively known as

247 ires daily administration of combinations of rifampin (RIF), isoniazid [isonicotinylhydrazine (INH)],

248 eptibility testing (DST) to isoniazid (INH), rifampin (RIF), moxifloxacin (MOX), ofloxacin (OFX), ami

249 merase (rpoB) gene that confer resistance to rifampin (RIF), the treatment of choice for tuberculosis

250 ere offered 9-month isoniazid (INH), 4-month rifampin (RIF), weekly rifapentine/isoniazid (RPT/INH) f

251 significantly associated with patients with rifampin (RIF)-resistant TB.

252 t infection (PJI), often in combination with rifampin (RIF).

253 etting up direct DST for isoniazid (INH) and rifampin (RIF).

254 rget of the first-line antituberculosis drug rifampin (Rif).

255 NAP inhibitor and current antibacterial drug rifampin (Rif).

256 Nigerian HIV-infected individuals (7.0% for rifampin [RIF] and 9.3% for RIF or isoniazid [INH]).

257 ex (MTBC)-negative, MTBC-positive (including rifampin [RIF] susceptible and RIF resistant), and nontu

258 Seven major TB drugs (rifampin [RIF], isoniazid [INH], linezolid [LZD], moxifl

259 In contrast, rifampin, rifabutin and rifapentine administered with va

260 ced in response to tuberculosis antibiotics (rifampin, rifabutin and rifapentine) were compared in pr

261 Rifampin, rifabutin or rifapentine administered with van

262 After 4 weeks of infection, rifampin, rifabutin, or rifapentine were administered, a

263 mance of GeneChip in detecting resistance to rifampin (RMP) and isoniazid (INH) and in detecting mult

264 (MTBC) are defined by resistance to at least rifampin (RMP) and isoniazid (INH).

265 s used in the United States-isoniazid (INH), rifampin (RMP), ethambutol (EMB), and pyrazinamide (PZA)

266 Since 1967, Rifampin (RMP, a Rifamycin) has been used as a first lin

267 resistance to isoniazid (katG and inhA) and rifampin (rpoB).

268 Rifampin's inhibition of TLR4 signaling was also observe

269 gatifloxacin-containing regimen for treating rifampin-sensitive pulmonary tuberculosis.

270 s 18 to 65 years of age with smear-positive, rifampin-sensitive, newly diagnosed pulmonary tuberculos

271 tion curves and peak serum concentrations of rifampin showed a more than proportional increase with d

272 0% and 100% for isoniazid, 98.4% and 50% for rifampin (specificity increased to 100% once the strains

273 and 335/336 rifampin-susceptible isolates as rifampin susceptible (specificity, 99.7%; 95% CI, 95.8 t

274 y, 98.7%; 95% CI, 95.8 to 99.6%) and 335/336 rifampin-susceptible isolates as rifampin susceptible (s

275 Newly identified patients with rifampin-susceptible pulmonary TB were enrolled in a fir

276 rare FQ resistance among the more prevalent rifampin-susceptible TB accounted for 50% of FQ-resistan

277 rare FQ resistance among the more-prevalent rifampin-susceptible TB accounted for 50% of FQ-resistan

278 (MDR-TB) as well as isoniazid-resistant but rifampin-susceptible TB.Methods: Published systematic re

279 Xpert MTB/RIF-confirmed rifampin-susceptible tuberculosis cases were recruited a

280 utation in rpoB, which encodes the canonical rifampin target, the beta subunit of RNA polymerase.

281 xycycline, linezolid, meropenem, penicillin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, a

282 atment adherence was better with 4 months of rifampin than 9 months of isoniazid (95% vs 68%, P < .00

283 related adverse events were less common with rifampin than isoniazid among people living with HIV (ri

284 nfer a survival advantage in the presence of rifampin, they may alter the normal process of transcrip

285 s a Trojan horse-like import of RBT, but not rifampin, through fhuE, only in nutrient-limited conditi

286 , nitrofurantoin, quinupristin-dalfopristin, rifampin, tigecycline, and vancomycin.

287 trimethoprim-sulfamethoxazole (TMP-SMX) and rifampin, TMP-SMX alone, rifampin alone, or tetracycline

288 mice exhibit tolerance to both isoniazid and rifampin to a degree proportional to the activation stat

289 inhibitor of NQO1 dicoumarol synergized with rifampin to promote intracellular killing of mycobacteri

290 While lineage 1, 3, and 4 strains developed rifampin tolerance, lineage 2 Beijing strains did not.

291 Two weeks of rifampin up to 35 mg/kg was safe and well tolerated.

292 (adjusted OR, 5.65; 95% CI, 0.93-34.47), and rifampin use (adjusted OR, 4.56; 95% CI, 0.74-27) were a

293 nsplantation, cytomegalovirus infection, and rifampin use) when compared with none of these factors c

294 tion, safety, and efficacy of four-months of rifampin vs nine-months of isoniazid among people living

295 Resistance to rifampin was linked to a partial duplication of the gene

296 Rifampin was more often or similarly completed to isonia

297 a substrate for CYP3A4, which is induced by rifampin, we evaluated the pharmacokinetic/pharmacodynam

298 ns of amikacin, doripenem, levofloxacin, and rifampin were quantitatively assessed using a validated

299 ifapentine with vancomycin were as active as rifampin with vancomycin against MRSA in rat foreign bod

300 udy, we evaluated rifabutin, rifapentine and rifampin, with and without vancomycin, in a rat model of

301 here was a nonlinear increase in exposure to rifampin without an apparent ceiling effect and a greate